CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project investigates the use of imatinib mesilate to treat patients with pneumonia caused by coronavirus. It aims to assess the drug's effectiveness, safety, and how it is processed in the body through a clinical trial involving 100 patients in intensive care units.
The accumulation of fluid in the lungs is a significant feature of the pathology in patients with severe Covid-19 infection.
This build up of fluid, contributes to difficulty in breathing and in some cases death.
This fluid in the lungs results in part from direct damage to cilia and mucus cells and resulting debris and in part due to plasma extravasation triggered by the immune response to infection and associated damage.
Imatinib, a generic marketed drug has been shown to reduce plasma extra…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Amsterdam
Type: Research institute
Activity type: Research Organisations
SME: No
Netherlands, Amsterdam
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Canada, St-Hubert
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
France, Le Plesiss Robinson
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
